# RareDiseaseArb — State of Bio 2026 > A screen of drugs approved by a foreign regulator (EMA, EEA national registers via > the EMA Article 57 database, Health Canada, Swissmedic, PMDA) whose active moiety has > never been approved in the United States. This screens one prior-approval requirement > under FD&C Act §529; other voucher criteria also require assessment and human review. Each > candidate carries a machine-drafted §529 eligibility checklist plus PubMed, > ClinicalTrials.gov, ChEMBL, Orphadata, EU orphan-designation and FDA complete-response > signals. Automated agents and AI assistants are welcome to read every page here. Data snapshot: UNII 4Aug2026 · Drugs@FDA 19 Nov 2026 · Orange Book 19 Nov 2026 · EMA 19 Nov 2026 · Health Canada 19 Nov 2026 · Swissmedic 19 Nov 2026 · PMDA 19 Nov 2026 · GSRS relationship graph Generated: 2026-11-19 ## Headline numbers - Candidates (approved abroad, never in the US): 342 - Multi-regulator candidates: 23 - Dossier-only (unnamed) rows: 29; rows queued for human review: 9 - Foreign approval rows screened: 18135; of which already in the US record: 2031 - Disclosed PRV deals tracked (filings and seller disclosures): 40; latest six RPD deals US$ 190.0M–210.0M; record US$ 350.0M (2015); market data reviewed through 2026-11-19. This sample is incomplete and includes unclosed agreements. - Months until the rare-pediatric PRV programme sunset: 34 ## Pages - [Almanac (home)](https://raredisease.arbs.carterpry.com/): searchable shortlist, PRV market charts, pipeline breadth, approval map - [Candidate table, static HTML](https://raredisease.arbs.carterpry.com/candidates): all candidates in one plain table, no JavaScript needed - [Full candidate list, plain text](https://raredisease.arbs.carterpry.com/llms-full.txt): one section per candidate incl. the §529 checklist - [Card-list dashboard](https://raredisease.arbs.carterpry.com/list/): interactive cards with notes export/import - [Funnel report](https://raredisease.arbs.carterpry.com/funnel): how 18k foreign approval rows narrow to the shortlist - [Accuracy audit](https://raredisease.arbs.carterpry.com/audit): harness results and known limitations - [Raw pipeline output, JSON](https://raredisease.arbs.carterpry.com/data/summary.json): everything above, machine-readable ## Notes - Charts labelled "RareDiseaseArb pipeline" and "Filings & seller disclosures" use real data; charts labelled "Illustrative" (disease areas, modalities) are design placeholders. - Nothing on this site is investment, legal, business or tax advice.